Please assess the completion status of the following clinical trial:

Trial Title: Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for NeoCirc-001, 001A and 001B -~Target population for informed consent:~* neonates 24 to 32+6 weeks´ gestation,~* postnatal age \<72 hours;~Infants eligible for circulatory failure pathway:~* parental informed consent obtained;~* The infants will be assessed, as per routine clinical practice, for clinical signs indicating infants at risk of poor perfusion, and will be recruited if they develop haemodynamic insufficiency defined as: either two or more of: (i) Mean blood pressure (MBP) \< gestational age (GA)-1 mmHg (invasive/non-invasive, two readings 15 min apart); (ii) SVC flow \< 51 ml/kg/min; (iii) capillary refill time (CRT) \> 4 sec; (iv) Lactate \> 4 mmol/l (v) Base excess \<-9 mmol/l or: MBP \< GA -5 mmHg (invasive/non-invasive, two readings 15 min apart)~Exclusion Criteria: NeoCirc-001, 001A and 001B -~* non-viability;~* congenital hydrops or malformations likely to affect cardiovascular adaptation;~* surgery planned within 72 hours of birth;~* chromosomal anomalies;~* informed consent form (ICF) not signed.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Dobutamine (Type: EXPERIMENTAL): Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).

Based on this trial design, predict the completion outcome and termination type (if applicable).